Compass Therapeutics to Participate in Upcoming May Investor Events
Rhea-AI Summary
Compass Therapeutics (Nasdaq:CMPX) will participate in two May 2026 investor conferences focused on biotechnology and oncology.
The company presents at the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq on May 19 at 1:30 PM ET, and at the 2026 Stifel Virtual Targeted Oncology Forum on May 20 at 11:30 AM ET. Both presentations are accessible via webcast, with replays available on the company’s Events page. Management will be available for one-on-one investor meetings arranged through conference representatives.
Positive
- None.
Negative
- None.
News Market Reaction – CMPX
In the May 12 session, CMPX gained 2.19%, reflecting a moderate positive market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 05 | Earnings and update | Positive | +0.5% | Q1 2026 results, positive tovecimig data, strong cash runway into 2028. |
| Apr 27 | Clinical data detail | Positive | -64.4% | COMPANION-002 Phase 2/3 data showing PFS and ORR benefit in biliary cancer. |
| Apr 24 | Clinical data preview | Neutral | -64.4% | Announcement of upcoming webcast to review COMPANION-002 topline endpoints. |
| Mar 05 | Full-year earnings | Positive | -2.8% | 2025 results, tovecimig ORR success, IND clearance for CTX-10726, runway to 2028. |
| Jan 06 | Corporate update | Positive | -1.6% | Pipeline progress, tovecimig PFS/OS plans, CTX-8371 expansions, $209M cash estimate. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news with generally positive clinical and financial messages often coincided with weak or negative price reactions, especially around key tovecimig data.
Over the past six months, Compass reported multiple clinically meaningful updates on tovecimig and other bispecific programs alongside solid cash runway into 2028. Notably, the COMPANION-002 Phase 2/3 trial met key efficacy endpoints, yet the stock saw a sharp negative move around the detailed data release on April 27, 2026. Subsequent earnings on May 5, 2026 highlighted positive data and a $195M cash balance with a modestly positive reaction, suggesting mixed market confidence despite advancing programs.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of May.
Details are as follows:
H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Date: Tuesday, May 19, 2026
Time: 1:30 PM ET
Webcast Link: https://journey.ct.events/view/bc55d2f9-d121-4f7d-8129-1f69f201bd7f
2026 Stifel Virtual Targeted Oncology Forum
Date: Wednesday, May 20, 2026
Time: 11:30 AM ET
Webcast Link: https://event.summitcast.com/view/SScpdhHfwE8g9WsS8WcTax/QuhrzDf8Wdgui7i3FhuDb6
Virtual/Replay availability: Presentations will be archived on Compass’ Events page.
Compass’ management will be available for one-on-one meetings during all events. Interested investors should contact their respective representatives to request meetings.
About Compass Therapeutics
Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, MA. Compass is a clinical-stage, oncology-focused biopharmaceutical company discovering and developing proprietary antibody-based therapeutics to treat multiple diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system and tumor growth. Compass has a robust pipeline of novel product candidates designed to target multiple key biological pathways to drive an effective anti-tumor response, including angiogenesis modulation, immune activation within the tumor microenvironment, and reduction of tumor-driven immunosuppression. The company is advancing discovery candidates through clinical development to commercial-stage assets. For more information, visit www.compasstherapeutics.com.
Investor Contact
ir@compasstherapeutics.com
Media Contact
Anna Gifford, Chief of Staff
media@compasstherapeutics.com
617-500-8099
